| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| W M Drak. Experience with pegvisomant in the treatment of acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 11 Suppl A. 2002-01-28. PMID:11527081. |
established modalities of therapy for acromegaly (surgical adenomectomy, external beam pituitary irradiation, oral dopamine agonists, and injectable somatostatin analogues) have as their common goal the lowering of circulating growth hormone (gh) levels, with a consequent reduction in serum insulin-like growth factor i (igf-i). |
2002-01-28 |
2023-08-12 |
Not clear |
| W M Drak. Experience with pegvisomant in the treatment of acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 11 Suppl A. 2002-01-28. PMID:11527081. |
pegvisomant is a gh receptor antagonist that inhibits gh receptor dimerization and has a powerful ability to lower serum igf-i levels in patients with active acromegaly. |
2002-01-28 |
2023-08-12 |
Not clear |
| J J Kopchick, S Okad. Growth hormone receptor antagonists: discovery and potential uses. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 11 Suppl A. 2002-01-28. PMID:11527080. |
high levels of gh can lead to gigantism or a clinical syndrome termed acromegaly, and also have been implicated in diabetic eye and kidney damage. |
2002-01-28 |
2023-08-12 |
human |
| K M Morrison, Z Wu, M Bidlingmaier, C J Strasburge. Findings and theoretical considerations on the usefulness of the acid-labile subunit in the monitoring of acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 11 Suppl A. 2002-01-28. PMID:11527090. |
growth hormone (gh) action induces a variety of biochemical factors of which insulin-like growth factor i (igf-i) is conventionally measured for the diagnosis and monitoring of gh-related disorders such as gh deficiency or acromegaly. |
2002-01-28 |
2023-08-12 |
Not clear |
| K M Morrison, Z Wu, M Bidlingmaier, C J Strasburge. Findings and theoretical considerations on the usefulness of the acid-labile subunit in the monitoring of acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 11 Suppl A. 2002-01-28. PMID:11527090. |
in the treatment of active acromegaly with the gh receptor antagonist pegvisomant, als showed a closer correlation with the change in ring size, measured as a clinical indicator of disease activity, than did igf-i or igfbp-3. |
2002-01-28 |
2023-08-12 |
Not clear |
| D R Clemmon. Commercial assays available for insulin-like growth factor I and their use in diagnosing growth hormone deficiency. Hormone research. vol 55 Suppl 2. 2002-01-07. PMID:11684882. |
generally, studies have shown that igf-i is sensitive and specific for the diagnosis of acromegaly, but screening for gh deficiency (ghd) is less precise. |
2002-01-07 |
2023-08-12 |
Not clear |
| D Ferone, R Pivonello, S Lastoria, A Faggiano, M L Del Basso de Caro, P Cappabianca, G Lombardi, A Cola. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy. Clinical endocrinology. vol 54. issue 4. 2002-01-03. PMID:11318782. |
gh and prl cosecretion frequently occurs in acromegaly and the sensitivity of both hormones to somatostatin analogs (sa) and dopamine agonists (da) alone or in combination, is still debated. |
2002-01-03 |
2023-08-12 |
Not clear |
| F Cordido, A Peñalva, T Martinez, F F Casanueva, C Diegue. Effect of acute pharmacological modulation of plasma free fatty acids on GH secretion in acromegalic patients. Clinical endocrinology. vol 54. issue 4. 2002-01-03. PMID:11318787. |
in acromegaly gh secretion is markedly increased due in most cases to a gh secreting pituitary adenoma. |
2002-01-03 |
2023-08-12 |
Not clear |
| W M Drake, C Parkinson, G M Besser, P J Traine. Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly. Trends in endocrinology and metabolism: TEM. vol 12. issue 9. 2001-12-28. PMID:11595543. |
one such compound, b2036, has been conjugated to polyethylene glycol to produce a drug, pegvisomant, that has a powerful ability to lower circulating concentrations of insulin-like growth factor i (igf-i), the principal mediator of gh action, in patients with acromegaly and to improve the symptoms and signs associated with gh excess. |
2001-12-28 |
2023-08-12 |
Not clear |
| W M Drake, C Parkinson, G M Besser, P J Traine. Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly. Trends in endocrinology and metabolism: TEM. vol 12. issue 9. 2001-12-28. PMID:11595543. |
this article describes the mechanism of action of gh-receptor antagonists, reviews the preclinical and clinical data on the use of pegvisomant and discusses some of the challenges that lie ahead in judging the efficacy of a treatment that, unlike established therapies for acromegaly, does not aim to modify the underlying cause of acromegaly, namely excess gh secretion, but aims to lower serum igf-i levels to normal. |
2001-12-28 |
2023-08-12 |
Not clear |
| L Prieto, S M Web. Quality of life assessment in patients with GH deficiency and acromegaly. The Journal of clinical endocrinology and metabolism. vol 86. issue 12. 2001-12-28. PMID:11739478. |
quality of life assessment in patients with gh deficiency and acromegaly. |
2001-12-28 |
2023-08-12 |
Not clear |
| C Parkinson, W D Ryder, P J Traine. The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. The Journal of clinical endocrinology and metabolism. vol 86. issue 11. 2001-12-13. PMID:11701684. |
the relationship between serum gh and serum igf-i in acromegaly is gender-specific. |
2001-12-13 |
2023-08-12 |
human |
| C Parkinson, W D Ryder, P J Traine. The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. The Journal of clinical endocrinology and metabolism. vol 86. issue 11. 2001-12-13. PMID:11701684. |
in patients with acromegaly, there is a linear association between log10 serum gh and igf-i. |
2001-12-13 |
2023-08-12 |
human |
| C Parkinson, W D Ryder, P J Traine. The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. The Journal of clinical endocrinology and metabolism. vol 86. issue 11. 2001-12-13. PMID:11701684. |
we report the influence of gender on the relationship between serum gh and igf-i in subjects with active acromegaly. |
2001-12-13 |
2023-08-12 |
human |
| C Parkinson, W D Ryder, P J Traine. The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. The Journal of clinical endocrinology and metabolism. vol 86. issue 11. 2001-12-13. PMID:11701684. |
this study demonstrates a gender difference in the relationship between serum gh and igf-i in patients with active acromegaly consistent with relative gh resistance observed in normal and ghd females, which may, in part, be mediated by e. this observation has important implications for the use of igf-i as a measure of disease activity. |
2001-12-13 |
2023-08-12 |
human |
| T K Hansen, S Thiel, R Dall, A M Rosenfalck, P Trainer, A Flyvbjerg, J O Jørgensen, J S Christianse. GH strongly affects serum concentrations of mannan-binding lectin: evidence for a new IGF-I independent immunomodulatory effect of GH. The Journal of clinical endocrinology and metabolism. vol 86. issue 11. 2001-12-13. PMID:11701711. |
subsequently, we studied 30 healthy persons and 25 gh-deficient (ghd) patients randomized to treatment with gh or placebo in a double-blinded manner, and further included samples from 23 patients with active acromegaly examined before and after treatment with octreotide or the gh-receptor antagonist pegvisomant for 3 months. |
2001-12-13 |
2023-08-12 |
human |
| M Andersen, C H Jensen, R K Støving, J B Larsen, H D Schrøder, B Teisner, C Hage. Fetal antigen 1 in healthy adults and patients with pituitary disease: relation to physiological, pathological, and pharmacological GH levels. The Journal of clinical endocrinology and metabolism. vol 86. issue 11. 2001-12-13. PMID:11701723. |
however, we found that pharmacologically induced changes in gh levels during weeks to months had a corresponding direct or indirect effect on fa1 levels in patients with gh deficiency or acromegaly. |
2001-12-13 |
2023-08-12 |
human |
| W Hasan, T Cowen, P S Barnett, E Elliot, P Coskeran, P M Boulou. The sweating apparatus in growth hormone deficiency, following treatment with r-hGH and in acromegaly. Autonomic neuroscience : basic & clinical. vol 89. issue 1-2. 2001-12-04. PMID:11474638. |
since active acromegaly involves excess gh secretion and hyperhidrosis, skin biopsies and sweat tests were also carried out on a group of these patients, as well as on control subjects. |
2001-12-04 |
2023-08-12 |
human |
| W Hasan, T Cowen, P S Barnett, E Elliot, P Coskeran, P M Boulou. The sweating apparatus in growth hormone deficiency, following treatment with r-hGH and in acromegaly. Autonomic neuroscience : basic & clinical. vol 89. issue 1-2. 2001-12-04. PMID:11474638. |
a trophic effect of gh on sweat gland epithelium and/or on the associated nerves is proposed, supported by the observation that in acromegaly the size of sweat gland acini and the density of innervation to the sweat glands was greater than in controls. |
2001-12-04 |
2023-08-12 |
human |
| M Fassnacht, B Capeller, W Arlt, T Steck, B Alloli. Octreotide LAR treatment throughout pregnancy in an acromegalic woman. Clinical endocrinology. vol 55. issue 3. 2001-10-25. PMID:11589686. |
we report a 24-year-old woman with active acromegaly despite pituitary surgery and irradiation who received continuous octreotide lar treatment for the control of gh excess throughout her pregnancy. |
2001-10-25 |
2023-08-12 |
Not clear |